




The relative strengths and weaknesses of Nurix Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Nurix Therapeutics Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 122% points. The greatest weakness of Nurix Therapeutics Inc is the variable Research and Development, reducing the Economic Capital Ratio by 9.8% points.

The company's Economic Capital Ratio, given in the ranking table, is 326%, being 111% points above the market average of 215%.

Input Variable	Value in 1000 USD
Assets, Current	619,387
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	95,854
Liabilities, Non-Current	46,496
Other Assets	32,199
Other Compr. Net Income	805
Other Expenses	270
Other Liabilities	0
Other Net Income	0
Other Revenues	74,277
Property and Equipment	17,757
Research and Development	221,632
Selling, General and Administrative Expense	45,944

Output Variable	Value in 1000 USD
Assets	669,343
Liabilities	142,350
Expenses	267,846
Revenues	74,277
Stockholders Equity	526,993
Net Income	-193,569
Comprehensive Net Income	-193,166
BaseVar	577,310
ECR before LimitedLiability	235%
Economic Capital Ratio	326%